Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonidegib (LDE225) for Basal Cell Carcinomas in Gorlin Syndrome
NCT00961896Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Aug 2010
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of sonidegib in basal cell carcinoma (BCC), sponsored by Novartis. Started Jul 2009; status: completed.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00961896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961896.